雙胍類市場 - 按藥物類型（品牌、學名藥）、劑型（片劑、口服溶液）、配方（速釋、緩釋）、配銷通路（醫院、零售、線上藥局）、全球預測，2024 - 2032

Biguanides Market - By Drug Type (Branded, Generic), Dosage Form (Tablets, Oral Solutions), Formulation (Immediate-release, Extended-release), Distribution Channel (Hospital, Retail, Online Pharmacies), Global Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球第 2 型糖尿病 (T2DM) 盛行率不斷上升，預計 2024 年至 2032 年雙胍類市場規模的複合年成長率將達到 2.9%。根據世界衛生組織的數據，全球約有 4.22 億人受到糖尿病影響，其中大多數居住在低收入和中等收入國家。生活方式的改變導致久坐的習慣和不良的飲食選擇，導致糖尿病發病率不斷上升。此外，不斷擴大的老年人口，容易患上糖尿病等與年齡相關的疾病，也需要有效的管理策略，進一步刺激了對雙胍療法的需求。

藥物研發的快速進步導致創新製劑和聯合療法的推出，以提高雙胍的療效和耐受性。這些進步迎合了不斷變化的患者需求和偏好。此外，旨在提高糖尿病管理意識和提供負擔得起的醫療保健解決方案的積極政府舉措將促進行業擴張。

雙胍類藥物產業分為藥品種類、劑型、劑型、配銷通路和區域。

按劑型分類，到 2032 年，學名藥市場規模預計將成長 3.4%。學名藥的可用性增加正在提高這種療法的可及性，特別是在醫療資源有限或預算有限的地區。此外，學名藥經過嚴格的監管評估，以確保生物等效性和治療功效，從而增強醫療保健專業人員和患者對其安全性和有效性的信心。

由於廣泛的可近性和以患者為中心的服務，零售藥房配銷通路領域的雙胍類市場預計在 2024 年和 2032 年期間複合年成長率為 3%。零售藥局憑藉其廣泛的網路和便利的地理位置，成為雙胍藥物的主要分銷管道，確保了廣泛的市場覆蓋範圍和患者的可用性。此外，零售藥局透過向接受糖尿病管理處方療法的個人提供有價值的諮詢和支持服務，幫助患者教育和藥物依從性。

在生活方式不斷改變和人口老化的支持下，到 2032 年，歐洲雙胍行業規模將以 3.1% 的複合年成長率大幅成長。旨在解決糖尿病盛行率和促進預防性醫療保健措施的積極政府措施將推動區域市場的成長。此外，歐洲國家強大的醫療基礎設施和報銷政策也促進了雙胍療法的獲得。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Ltd.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd.
Merck & Co., Inc.
Sanofi
Takeda Pharmaceutical Company Limited.
Teva Pharmaceuticals Industries Ltd.
Zydus Group

簡介目錄

Product Code: 8309

Biguanides Market size is expected to record 2.9% CAGR from 2024 to 2032, driven by the rising prevalence of type 2 diabetes mellitus (T2DM) globally. As per WHO, approximately 422 million individuals globally are affected by diabetes, with the majority residing in low- and middle-income nations. The influx of lifestyle changes leading to sedentary habits and poor dietary choices is contributing to the growing incidence of diabetes. Additionally, the expanding geriatric population, prone to age-related conditions, such as diabetes is also necessitating effective management strategies, further fueling the demand for biguanide-based therapies.

Rapid advancements in pharmaceutical R&D are leading to the introduction of innovative formulations and combination therapies for enhancing the efficacy and tolerability of biguanides. These advancements are catering to the evolving patient needs and preferences. Furthermore, proactive government initiatives aimed at raising awareness about diabetes management and providing affordable healthcare solutions will foster the industry expansion.

The biguanides industry is classified into drug type, dosage form, formulation, distribution channel and region.

By dosage form, the market size from the generic segment is poised to witness 3.4% growth rate through 2032. The expiration of patents on branded biguanide medications has led to the entry of generic alternatives for offering cost-effective treatment options for patients and healthcare providers. This increased availability of generic formulations is enhancing the accessibility to this therapy, particularly in regions with limited healthcare resources or budget constraints. Additionally, generic medications undergo stringent regulatory evaluations to ensure bioequivalence and therapeutic efficacy, instilling confidence among healthcare professionals and patients regarding their safety and efficacy.

Biguanides market from the retail pharmacies distribution channel segment is anticipated to observe a 3% CAGR during 2024 and 2032, owing to widespread accessibility and patient-centric service. With their extensive network and convenient locations, retail pharmacies serve as key distribution channels for biguanide medications, ensuring broad market reach and availability to patients. Furthermore, retail pharmacies help in patient education and medication adherence by providing valuable counseling and support services to individuals with prescribed therapies for diabetes management.

Europe biguanide industry size will grow significantly at 3.1% CAGR through 2032, backed by growing lifestyle changes and aging population. The proactive government initiatives aimed at addressing diabetes prevalence and promoting preventive healthcare measures will propel the regional market growth. Moreover, robust healthcare infrastructure and reimbursement policies in European countries are also facilitating access to biguanide therapies.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of diabetes
  - 3.2.1.2 High preference for biguanides as first line treatment
  - 3.2.1.3 Advancements in drug delivery technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with biguanides
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Branded
5.3 Generic

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Tablets
6.3 Oral solutions

Chapter 7 Market Estimates and Forecast, By Formulation, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Immediate-release
7.3 Extended-release

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa